Delaware Justices Affirm BLB&G's Post-Trial Win in Williams, Establishing Critical Delaware Legal Precedent on Poison Pills
November 7, 2021
On November 3, 2021, the Delaware Supreme Court issued an order affirming the Chancery Court's injunction requiring the redemption of the "Poison Pill" adopted by The Williams Cos. in 2020. This follows the BLB&G team's trial win in February 2021, when the Court struck down what it described as the novel and “extreme” Pill, which the Court found to be targeted at stockholder activism generally, finding that the Williams board failed to show that the Pill was a reasonable and measured response to a specific threat.
This week's affirmation of the decision represents a victory not only for activist investors but for all stockholders. In affirming the Court of Chancery’s decision, the Delaware Supreme Court confirmed that:
- Unocal remains the proper standard for analyzing the validity of any poison pill;
- Fiduciaries seeking to adopt a poison pill must identify a legitimate threat as
generalized concerns about stockholder activism by Delaware fiduciaries does not constitute a cognizable threat that could justify adoption of a poison pill; and
- The “nuclear missile” poison pill adopted by the Williams board with its “extreme, unprecedented collection of features” including a 5% trigger, acting-in-concert or "Wolfpack" provision, daisy chain clause and faulty passive investor “carve out” was not a proportional response to any recognized threat to the company or its policies.
We believe that boards will take heed of the Williams decision and, hopefully, will be less likely to indiscriminately target stockholder activism in the future.
For background on this case, please visit the case description linked to under the Related Case section of this page.
- News Press Coverage: Williams Companies Stockholder Litigation Trial Challenging Novel Anti-Shareholder Corporate Governance Provision January 13, 2021 Learn More
- Events BLB&G Partner Mark Lebovitch to Speak at NYU Law's Institute for Corporate Governance & Finance Roundtable, "Poison Pills after Williams Cos." April 27, 2022 Learn More
- Publications "Acting-in-Concert Poison Pills: This Pill Comes With a Silencer" by Mark Lebovitch, Gregory V. Varallo, and Thomas James published by The New York Law Journal November 25, 2020 Learn More
- News BLB&G Partner Greg Varallo Quoted in Law360 Article Covering Significant Happenings in Delaware's Legal Industry in 2021 December 9, 2021 Learn More
- News BLB&G Allianz Structured Alpha Funds Team Announces New Case Filing October 16, 2020 Learn More
- News BLB&G Partner Gregory V. Varallo Quoted in Law360 Article Covering the Appointment of Vice Chancellor Kathaleen S. McCormick as Delaware Chancery Court Successor April 9, 2021 Learn More
- News Delaware Law Weekly Highlights BLB&G Associate Mae Oberste's Appointment to the DSBA's Executive Committee July 20, 2022 Learn More
- News Robert "Rocky" Kravetz Joins BLB&G as Trial Counsel in the New York Office January 2021 Learn More